KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Acquisitions & Divestments (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $40.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Change in Acquisitions & Divestments changed N/A year-over-year to $40.0 million, compared with a TTM value of $40.0 million through Sep 2025, changed 0.0%, and an annual FY2025 reading of $42.0 million, up 5.0% over the prior year.
  • Change in Acquisitions & Divestments was $40.0 million for Q3 2024 at Teva Pharmaceutical Industries, up from $1.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $107.0 million in Q2 2021 and bottomed at $1.0 million in Q3 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $25.3 million, with a median of $6.0 million recorded in 2020.
  • The sharpest move saw Change in Acquisitions & Divestments tumbled 97.56% in 2020, then surged 3466.67% in 2021.
  • Year by year, Change in Acquisitions & Divestments stood at $3.0 million in 2020, then soared by 533.33% to $19.0 million in 2021, then plummeted by 94.74% to $1.0 million in 2022, then surged by 3900.0% to $40.0 million in 2024.
  • Business Quant data shows Change in Acquisitions & Divestments for TEVA at $40.0 million in Q3 2024, $1.0 million in Q3 2022, and $3.0 million in Q2 2022.